1Analysis of the significance of the new disease name"metabolic dysfunction-associate steatotic liver disease"CHEN Si-tong, XU Hang-fei, WEI Xiao-die, ZHAO Jin-han, ZHANG Yang, ZHANG JingSYMPOSIUM·NONALCOHOLIC FATTY LIVER DISEASE1-62Clinical research progress of nonalcoholic fatty liver disease and liver transplantationMAI Zi-ling, CHANG Bing, LI Yi-lingSYMPOSIUM·NONALCOHOLIC FATTY LIVER DISEASE7-10,163Endocrine disease and nonalcoholic fatty liver diseaseCAO Huan-yi, GUAN Hai-xia, FU Xiao-yingSYMPOSIUM·NONALCOHOLIC FATTY LIVER DISEASE11-164Clinical research progress of hepatitis B virus infection concurrent with metabolic dysfunction-associated fatty liver diseaseMA Xiao-yan, GENG Nan, RUI Fa-juan, NI Wen-jing, SHI Jun-ping, LI JieSYMPOSIUM·NONALCOHOLIC FATTY LIVER DISEASE17-21,325Epidemiological status and prevention and treatment progress of nonalcoholic fatty liver disease in childrenZHANG Xin-he, GUAN LinSYMPOSIUM·NONALCOHOLIC FATTY LIVER DISEASE22-286Nonalcoholic fatty liver disease-related hepatocellular carcinoma:what we know and unknownDENG Chao-hua, SHI Jun-pingSYMPOSIUM·NONALCOHOLIC FATTY LIVER DISEASE29-327Expert consensus on off-label drug use of Liaoning province in hematological diseases(2023 edition)The Lymphatic System Foundation and Clinical Immunity Branch of Liaoning Immune Society,Shenyang 110001,China, YANG WeiGUIDELINE AND CONSENSUS33-418Clinical analysis of BTK inhibitors combined with basic chemotherapy in newly diagnosed double expression diffused large B cell lymphomaYANG Dan, LI Feng, YANG Fei-fei, ZHAO You-cai, XU Yan-li, ZHANG Xue-zhong, ZHANG Xiu-qunORIGINAL CONTRIBUTION42-489Hypoxia-inducible factor prolyl hydroxylase inhibitor on the effect of infection events in patients with peritoneal dialysisDING Jia-xiang, REN Xiao-ying, FANG Xiao-wan, WANG Mei, YANG Qing-huaORIGINAL CONTRIBUTION49-53,8510Remnant cholesterol is associated with the risk of mildly reduced estimated glomerular filtration rateWANG Peng-bo, YE Ning, GUO Xiao-fan, WU Jing, SUN Ying-xianORIGINAL CONTRIBUTION54-5811Efficacy of low-dose and standard-dose Rituximab in patients with primary membranous nephropathyLIU Ai-chun, LIANG Yao-xian, ZHAO Xin-ju, WU Bei, WANG Yi-na, YAN Yu, DONG Bao, CAI Mei-shun, ZUO LiORIGINAL CONTRIBUTION59-6312Clinical efficacy and safety of Roxadustat in the treatment of renal anemia in patients with undergoing maintenance hemodialysis combined with viral hepatitisCHEN Li, ZHANG Wen-yu, CHANG Wen-xiuORIGINAL CONTRIBUTION64-6713GSDME,a molecule related to pyroptosis of CD34+cells in patients with myelodysplastic syndromeREN Xiao-tong, YU Shun-jie, GUO Xin-yu, LIU Zhao-yun, SHAO Zong-hong, FU Rong, LI Li-juanORIGINAL CONTRIBUTION68-74 